Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable 1 colorectal liver metastases: a multicenter study Tumor resection is the most effective method for achieving long-term survival in 2 patients with advanced liver-limited colorectal metastases (CRLMs). When complete 3 resection was performed successfully for patients with liver-limited CRLMs, a 5-year 4 survival rate of 40-50% could be achieved [1] [2] [3] [4] . Since the introduction of effective 5 chemotherapy, many primarily unresectable CRLMs can be considered resectable after 6 chemotherapy 5, 6 . However, "resectability" always depends on the judgment of individual 7 surgeons and/or institutional policies. An objective point of view is essential to treat the 8 patients appropriately.
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The Kyushu Study Group of Clinical Cancer (KSCC) previously reported the safety 10 and efficacy of neoadjuvant chemotherapy with mFOLFOX6 + bevacizumab for 11 advanced liver metastases of colorectal cancer 7 . In this study, "advanced liver metastasis" 12 was defined by the H-factor categories of H2 and H3 according to the guidelines of the 13 Japanese Society for Cancer of the Colon and Rectum 8, 9 . Generally, H2/H3 lesions are Takatsuki M et al. Pancreatic Surgery, and each surgeon performed more than 50 hepatectomies per year.
MATERIALS AND METHODS
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The actual evaluation was performed as follows. The 72 imaging scans were presented 21 on a screen in random order, and each scan was assessed by all reviewers at the same time.
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Only minimal information, such as the tumor location, was provided when the scans were 23 presented, and the timing of imaging (baseline vs. after chemotherapy), scans of other sites, patient information, and treatment information were not provided. As mentioned 1 before, each reviewer was blinded to the other reviewers' voting, and they were not 2 permitted to discuss their decisions with each other. Patients were considered "resectable" 3 if 3 or more reviewers provided a grade of 1 or 2. Resectability was evaluated as the 4 incidence of "resectable" grades. on imaging studies with discussion with each other, and patient characteristics were fully 8 described. The grading of resectability followed that described in Study 1.
9
The actual evaluation was performed as follows. The 72 scans (baseline and after 
Statistics
18
The rate of resectability before and after chemotherapy were statistically tested with 
RESULTS
1
Study 1 2
The rate of resectability 3 Before chemotherapy, 13 patients (36.1%) were evaluated to be "resectable," whereas 4 after chemotherapy, 17 patients (47.2%) were evaluated to be "resectable". Although 5 there was no significant difference (p=0.21), the rate of resectability increased after 6 chemotherapy. Of the above-mentioned 13 patients determined to have "resectable" 7 lesions before chemotherapy, 3 patients were evaluated as "unresectable" after 8 chemotherapy, of whom 1 actually underwent a hepatectomy. In total, the actual number 9 of resections performed after chemotherapy was 15 (41.7%). Of 17 patients evaluated to 10 be "resectable" after chemotherapy, 7 patients (41.1%) were evaluated to be "unresectable" 11 before chemotherapy, and 5 of these 7 patients actually underwent a hepatectomy. Finally, 12 hepatectomy was performed for 11 (64.7%) of 17 patients evaluated to be "resectable" Table 2 .
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The voting patterns of the surgeons
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There was considerable inter-individual variation in the decision-making process, with 20 25-39% of lesions considered "resectable" and 2-15% of lesions considered (Table 3) . Although most physicians recognize that tumor resection is the most reliable method 10 for achieving long-term survival in patients with CRLMs, patients might not always 11 receive appropriate treatment because the decision concerning resectability depends on 12 the each individual surgeon's judgment. Several reports described extremely aggressive 13 approaches for achieving R0 resection for advanced CRLM, including extracorporeal 14 liver resection or hepatic vein reconstruction 8, 11 . However, these types of surgery are not 15 available in all centers, and thus, it is important to evaluate the assessment of resectability 16 from a multicenter perspective. According to this study, although there were considerable In principle, the evaluation procedure in this study referenced the CELIM study from
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Germany and Austria, which demonstrated the efficacy of neoadjuvant chemotherapy for unresectable CRLM using cetuximab 10 . Although the proportion of "resectable" 1 metastases at baseline was not different between the CELIM study (32%) and this study 2 (36%), the proportion of "resectable" metastases after chemotherapy was higher in the 3 CELIM study (60%) than in this study (47%). The reason for this discrepancy is not clear, 4 but it might be related to the method for determination of resectability. In the CELIM 5 study, resectability was categorized as "resectable," "chemotherapy preferred," or 6 "unresectable," whereas in this study, 5 different categories were used. The variation in 7 agreement among the different reviewers appeared to be larger in this study than in the 8 CELIM study, possibly because of the same reason. In addition, the difference in tumor 9 control between cetuximab and bevacizumab might affect the rate of resectability. The 10 rate of radical resection (27.8%) in this study is comparable to that in other studies using 11 bevacizumab 12, 13 ; however, the rate of resection after chemotherapy did not significantly 12 increase in this study, contrary to the findings in the CELIM study. Accordingly, the 13 evaluation procedure of resectability in the CELIM study might not be suitable when 14 bevacizumab is used, as observed in this study.
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Generally, the resectability of liver tumors is determined on the basis of both the tumor 16 location/number and liver function. In this study, we evaluated resectability based on 17 imaging studies only without considering liver function. Unlike hepatocellular carcinoma, 18 which generally develops in diseased liver states such as hepatitis B or C, most CRLMs 19 occur in normal livers, but after chemotherapy, drug-induced liver dysfunction is of great 20 concern concerning the utilization of aggressive hepatectomy 14, 15 . Accordingly, in 21 clinical settings, we must consider liver function to avoid liver failure after hepatectomy, especially after chemotherapy. However, the aim of this study was to provide an absolute 23 objective evaluation based on imaging studies only to avoid subjective evaluation based on other clinical factors. Even with experts from high-volume centers, there were 1 considerable discrepancies among the surgeons, but we believe the result of this study is 2 a good reference for physicians who participate in the treatment of colorectal cancer.
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Because of the discrepancy in the rate of resectability between the CELIM study and 4 this study, we performed Study 2, in which the surgeons fully discussed the cases with 5 each other and they were sufficiently apprised of the characteristics of the patients. Interestingly, the proportion of lesions deemed "resectable" after chemotherapy was 7 significantly higher than that in Study 1. The result illustrated that even though the 8 findings of imaging studies were the same, physicians are more likely to judge lesions to 9 be "resectable" when they know the scans were obtained after chemotherapy, possibly The voting patterns of the reviewers in study 1. The numbers in the graph indicated the 8 actual numbers for each category. The agreement in voting among the reviewers. If a reviewer issued a grade of 1
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(resectable) or 2 (borderline resectable) and the others issued a grade of 3 (chemotherapy 13 preferred) or 4 (unresectable), this was considered "disagreement." 
